Skip to main content

Table 1 patients’ clinical and treatment characteristics and survival-related factors on OS in univariate analysis

From: Additional radiation boost to whole brain radiation therapy may improve the survival of patients with brain metastases in small cell lung cancer

Characteristics

No. of patients (%)

Median OS (months)

P value

Sex

 Male

64 (87.0)

9.3

0.860

 Female

18 (22.0)

10.3

 

Age (y)

 Median

59

  

 Range

39–73

  

  < 65

44 (53.7)

12.3

0.349

  ≥ 65

38 (46.3)

9.2

 

KPS

  ≥ 70

76 (92.7)

11.2

0.032*

  > 70

6 (7.3)

5.0

 

Smoking history

 Yes

64 (78.0)

9.2

0.647

 No

18 (22.0)

10.3

 

Weight loss≥5%

 Yes

26 (31.7)

9.3

0.734

 No

56 (68.3)

10.2

 

Number of BMs

 1

21 (25.6)

12.6

0.034*

 2–3

24 (29.3)

10.3

 

  > 3

37 (45.1)

6.8

 

Interval from diagnosis of SCLC to BMs (month)

  ≤ 10

40 (48.7)

9.2

0.204

  > 10

42 (51.3)

10.3

 

Maximum diameter of the largest tumor (cm)

  ≤ 2.0

44 (53.6)

12.6

0.002*

  > 2.0

38 (46.3)

9.4

 

Symptomatic BMs

 Yes

27 (32.9)

9.0

0.039*

 No

55 (67.1)

10.3

 

Treatment regimen before BMs

 Concurrent CRT

28 (33.7)

9.8

0.880

 Sequential CRT

54 (66.3)

9.6

 

Extracranial disease status

 Progressive

15 (18.3)

5.1

0.016*

 Control

67 (81.7)

10.3

 

Brain RT regimen

 WBRT

49 (59.8)

8.5

0.004*

 WBRT plus boost

33 (40.2)

13.4

 
  1. *p < 0.05 was considered significant. KPS Karnofsky performance score, BM brain metastases, CRT chemoradiotherapy, RT radiation therapy, WBRT whole brain radiotherapy